Citi Starts Coherus Biosciences (CHRS) at Buy, 'Come for the Biosimilars, Stay for the I/O Pipeline'
Tweet Send to a Friend
(Updated - July 24, 2023 5:57 AM EDT)
Citi analyst Yigal Nochomovitz initiates coverage on Coherus Biosciences (NASDAQ: CHRS) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Citi analyst Yigal Nochomovitz initiates coverage on Coherus Biosciences (NASDAQ: CHRS) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
